AOD-9604 vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | Palmitoyl Tripeptide-1 |
|---|---|---|
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |